<DOC>
	<DOCNO>NCT00376129</DOCNO>
	<brief_summary>Protocol Title : Open-label , single center study evaluate savety efficacy intramuscular 12 week-course Alefacept patient atopic dermatitis . Study Phase : II Study Design : Open-label , single center Primary Study Objective : determine safety efficacy one course Alefasept administer 15 mg intramuscular ( IM ) injektion patient atopic dermatitis Secondary Study Objective : investigate key immunological parameter involve pathology common skin disease interpret clinical finding Number patient : 10 Study Population : Male female patient , least 18 year age atopic dermatitis , aktive inflammation , severity score 6-9 accord Langeland Rajika EASI &gt; 20 Treatment Groups : Alefacept administer 15 mg IM injection week 12 week , follow 12-week follow-up period .</brief_summary>
	<brief_title>Open-Label , Singel Center Study Alefacept Patients With Atopic Dermatitis</brief_title>
	<detailed_description>Atopic dermatitis common chronic eczematous skin disease , wich often begin early infancy run course remission exacerbation . T-lymphocytes play prominent role skin disease . represent majority skin-infiltrating cell patient suffer AD also increase level activate circulate T cell increase level marker lymphocyte activation L-selectin IL-2R .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>must give write informed consent must least 18 year age must diagnose atopic dermatitis fulfil diagnostic criterion Hanfin und Rajka active inflammation must severity score 69 accord Langeland Rajka EASI &gt; 20 must PGA `` moderate '' , '' severe '' , `` severe '' pruritus score `` moderate '' '' severe '' baseline must total lymphocyte count CD4+ lymphocyte count low limit normal Patients severe disease , might interfere evaluation AD Patiens severe disease organ system might put patient risk study might interfere evaluation Patients old 65 year Systemic treatment atopic dermatitis ( e.g . cyclosporine , mycophenolat mofetil , inferferongamma , PUVA ) systemic treatment immunosuppressive/immunomodulating substance ( e.g . azathioprin , methotrexate , biologics hyposensitization therapy ) indication within 28 day prior baseline local treatment atopic dermatitis pimecrolimus/tacrolimus , steroid &gt; class III , unstable use steroid &lt; class III , emollients local antiseptics/antibiotics , UVB , UVA within 14 day prior baseline Serious local infection ( e.g . cellulitis , abscess ) systemic infection ( e.g . pneumonia , septicemia ) within 3 month prior first dose Alefacept Congenital acquire immunodeficiency syndrome History invasive malignancy . Patients history treatmend squamous cell and/or basal call carcinoma limit skin exluded Laboratory clinical evidence active tuberculosis Current treatment therapy active tuberculosis tuberculosis prophylaxis female patient , unless postmenopausal surgically sterile , unwillingness practice effective contraception , define investigator , study . rhythm method use sole method contraception . Female patient consider become pregnant study exclude female patient currently pregnant breastfeed abnormal chemistry , i.e. , LFTs great three time upper limit normal Current enrollment investigational drug study previous participation study previous study Alefacept</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>